CTS 21166

Drug Profile

CTS 21166

Alternative Names: ATG-Z1; CTS-21166; ZPQ 21166

Latest Information Update: 21 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CoMentis
  • Class Nootropics; Small molecules
  • Mechanism of Action Amyloid precursor protein secretase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Alzheimer's disease

Most Recent Events

  • 21 Apr 2016 No recent reports on development identified - Phase-I for Alzheimer's disease in USA (IV)
  • 16 Oct 2014 Astellas Pharma exercises option to terminate its collaboration agreement with CoMentis
  • 25 Apr 2008 Astellas Pharma and CoMentis have entered into an exclusive collaboration agreement to develop and commercialise CTS 21166 worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top